Kornimate/medical-research-clean huggingface dataset:
large cell lymphoma pilot study iii

Conditions: Lymphoma, Large Cell; Lymphoma, Non-Hodgkin

Summary: the main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with hematopoietic stem cell support for children with large cell lymphoma

secondary objectives will include documenting the toxicity associated with the treatment regimen, and to estimate the response rates and survival of participants with large cell lymphoma treated on this protocol. patients will be treated with induction, consolidation, and maintenance treatment. induction mied chemotherapy - high dose methotrexate, ifosfamide, etoposide, and dexamethasone for 2 cycles. high-dose methotrexate 8 gm/m2 on day 1 with leucovorin rescue ifosfamide 2 gm/m2/day on days 2-4 (total of 3 days) etoposide (vp-16) 200 mg/m2/day on days 2-4 (total of 3 days) dexamethasone 40 mg/m2/day iv on days 1-4 (given iv or po daily x 4) intrathecal mha, age adjusted dosages. consolidation copadm chemotherapy for 2 cycles - cyclophosphamide, vincristine, prednisone, adriamycin, high-dose methotrexate copam#1 high dose methotrexate (hd mtx) 5 gm/m2 iv over 4 hours on day 1 with leucovorin rescue; doxorubicin 60 mg/m2 iv over 6 hours on day 2, vincristine 2.0 mg/m2 (2.0 mg max) day 1, cyclophosphamide 500 mg/m2/day (divided every 12 hours) days 2-4, prednisone 60 mg/m2 (divided bid) days 1-5, intrathecal mha, age adjusted dosages. copadm#2 - like copadm#1 except: 1. cyclophosphamide dose increased to 1 gm/m2/day divided every 12 hours on days 2-4, and 2. second dose of vincristine given on day 6. dac chemotherapy x 1 cycle - dexamethasone, cytarabine, and carboplatin carboplatin (auc of 8) day 1; ara-c 2 gm/m2/dose q12 x 2 day 2 dexamethasone 40 mg/m2/day days 1-4; itmha dose age adjusted. hematopoietic stem cell transplantation - high-dose cyclophosphamide and etoposide involved field radiation to the primary tumor will be given over 3-4 weeks. participants with cns disease at diagnosis will also receive cranial irradiation. maintenance chemotherapy vinblastine 6 mg/m2 iv weekly for one year

Eligibility criteria:
inclusion criteria: * patient must be previously untreated, except for steroids or emergency radiation therapy. * patient must be less than or equal to 18 years of age. * patient must have a histologic diagnosis of large cell non-hodgkin lymphoma. * the immunophenotype of tumor cells must be either t-cell or non-b-cell, non-t-cell. exclusion criteria: * participants with b-cell immunophenotype nhl.
early life nutritional exposures and long-term health and cognitive outcomes

Conditions: Overnutrition; Undernutrition

Summary: this study aims to investigate the relationship of the various exposures during infancy and childhood on later health and development of adolescents. various exposures to be assessed include, but not limit to, nutritional status, body composition, energy expenditure, dietary intake, micronutrient status, breastfeeding, lifestyle, and other environment exposures. the study will specifically aim to respond these research questions: 1.1 what are the factors associated with overweight, obesity, and stunted in adolescents? 1.2 what are the factors associated with increased risk of ncds during adolescence? 1.3 what are the factors associated with cognitive functioning during adolescence? since numerous variables were collected, additional research questions can be possibly studied or other interested variables can be included in the future.

a longitudinal data were collected in children in the northeast of thailand beginning at 4-6 months of age and every 2 months through 10-12 months of age while children had been given iron and/or zinc supplementation. biochemical, anthropometric, socio-demographic, feeding practices, and maternal characteristics data were collected. children were followed up at 9 years of age to assess the long-term consequences of supplementation and early life nutrition on cognitive functioning and growth. there is a need to continue the follow-up of this study in order to address the association between early nutritional exposures and risks of cardio-metabolic dysfunction and cognitive and behavioral development later in childhood, adolescence and adulthood. thus, we propose to follow-up these children during adolescence to assess the relationship of early life nutrition and exposures during infancy and childhood and outcomes including nutritional status, cognitive functioning, and risk for non-communicable diseases (ncds). findings from this study could provide awareness and information in developing policies and timely interventions to maintain optimal nutritional status throughout vulnerable life stages and reduce risks of ncds and disabilities later in life.

Eligibility criteria:
inclusion criteria: * apparently healthy children exclusion criteria: * none

Keywords: adolescent nutritional status body composition biochemical status
face-to-face tracheal intubation: a comparison of airtraq, glidescope and fastrach

Conditions: Intubation Difficult

Summary: trauma victims had to be intubated at the scene of area in different conditions. face-to-face intubation in an entrapped patient is one of these situations. the investigators want to compare the efficacy of glidescope, airtraq and fastrach in simulating face-ro-face intubation in adult patients aged between 18-60 years.

the investigators record the demographic and the airway data of the patients (thyromental distance, sternomental distance, mallampati score, mandibula protrusions, interincisor distance..etc). the hemodynamic data of the patients baseline preoperatively, after induction, after insertion of the device, after intubation, and 2 minutes intervals after intubation during the ten minutes. cormack-lehane grade of the videolaryngoscopes, insertion time, intubation time, need of optimisation maneuvers, mucosal damage, teeth and tongue damage, postoperative sore throat, hoarseness, dysphagia were recorded.

Eligibility criteria:
inclusion criteria: * 18-60 years of age * elective surgery requiring endotracheal intubation * normal airway variables * bmi\< 30 exclusion criteria: * \ 60 years * emergency procedures * known difficult airways * bmi\> 30
memory for flu facts and myths and effects on vaccine intentions

Conditions: Influenza Vaccines

Summary: objectives: to determine whether people systematically misremember the "myths" (false information) as true, and to assess effects on perceptions of risk and behavioral intentions.

public information campaigns often warn people about false and unreliable medical claims by juxtaposing "myths" and "facts." the effectiveness of such communications has rarely been assessed. we assessed whether people systematically misremember the "myths" (false information) as true, and to assess effects on perceptions of risk and behavioral intentions. in an experimental study, participants read either a published cdc flyer on "facts and myths" about the flu vaccine, or a "facts only" version; a separate control group read no flyer. participants completed the outcome measures either immediately or after 30 minutes. primary measures were memory for information about the flu presented in the flyer, ratings of perceived risks associated with the flu, and personal intentions to get vaccinated in the upcoming season. after a delay of 30 minutes, participants who read the "facts and myths" flyer systematically misremembered myths as facts. both versions of the flyer had the immediate effect of increasing intentions to get a flu vaccine, compared to the control group. after 30 minutes, however, participants who read the "facts and myths" flyer reported lower intentions to get vaccinated, compared to those who read the same flyer with no delay, and compared to all participants who read the "facts only" flyer. in sum, people show a bias to think that incompletely remembered information is true, turning "myths" into "facts." hence public information campaigns should emphasize information that is true. repeating false information, even as a warning, can create the unintended consequence of belief in the information.

Eligibility criteria:
inclusion criteria: * must be able to read and write fluent english exclusion criteria: -
a study of the safety of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders

Conditions: Disruptive Behavior Disorder

Summary: the primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders. data on the efficacy of the drug will also be collected. only patients who were enrolled in the previous related study would be eligible to participate.

this is an open-label study of an oral formulation of risperidone to be taken daily over 12 months by children and adolescents with conduct and other disruptive behavior disorders. it is an extension of a randomized, double-blind study (ris-int-79) comparing risperidone with placebo over 6 months in patients who had already shown response to the medication for a period of 12 weeks. efficacy assessments include: the conduct problem subscale of the nisonger child behavior rating form (n-cbrf), a measure of symptoms of conduct and other disruptive behavior disorders; visual analogue scale for the most troublesome symptom (vas-ms), a scale ranging from not troublesome to extremely troublesome; clinical global impression-severity of illness (cgi-severity), a measure of overall severity of illness; children's global assessment scale (c-gas), as assessment overall functioning. safety evaluations include incidence of adverse events, physical examinations, laboratory tests (biochemistry, hematology, and urinalysis), and electrocardiograms (ecgs). oral risperidone solution (1milligram/milliliter) daily for 1year. for patients weighing at least 50kg, start dose is 0.5ml/day. at investigator's discretion, dose may be increased (maximum 1.5ml/d over 5 days). patients under 50kg start at 0.25ml/d, increased, if required, to maximum 0.75ml/d.

Eligibility criteria:
inclusion criteria: * patients must have completed the double-blind study (cr002020) * patients must begin the present study within 7 days of taking the last dose of medication in the prior study (cr002020) exclusion criteria: * patients with hypersensitivity or intolerance to risperidone * patients with extrapyramidal symptoms (eps) not adequately controlled with medication * history of neuroleptic malignant syndrome, a rare psychotropic-drug reaction, which may be characterized by confusion, reduced consciousness, high fever or pronounced muscle stiffness * significant and untreated or unstable medical illness such as diabetes, hypertension * serious illness of the liver, kidney, or significant disturbances of the cardiac, pulmonary, gastrointestinal, endocrine, neurological system * pregnant or nursing females, or those lacking adequate contraception

Keywords: disruptive behavior disorder risperidone antipsychotropic agents child adolescent
novel organic kale products for prevention of obesity/type 2 diabetes

Conditions: Type2 Diabetes

Summary: investigating the health beneficial effects of freeze-dried brassica oleracea var. acephala with a high content of fibers, protein, vitamin, minerals, and secondary metabolites on patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes, dietary treatment and/or with oral anti-diabetics * diabetes debut \> 30 year * plasma fasting blood glucose \> 4mm and \< 12 mm * hba1c \> 43 and ≤ 108 mmol/mol * bmi between 23-40 kg/m2 * fasting triglyceride \> 1.7 mmol/l and hdl-cholesterol, men: \< 1.03 mmol/l and women: 1.29 mmol/l. exclusion criteria: * participating or have been participating in other clinical trials within the last 2 months. * in treatment with insulin, systemic glucocorticoids, glitazones or glp-1 analogs. * cardiovascular-, physiological-, neurological-, and/or kidney diseases. * alcohol- or pill abuse. * acute diseases. * blood pressure ≥ 160/100 * pregnant or breastfeeding women.
safety, tolerability, and immunogenicity of zoster vaccine live (zostavax™) in healthy adults in india (v211-025)

Conditions: Herpes Zoster; Shingles

Summary: this study will determine if zostavax™ is safe, tolerable, and immunogenic in healthy adults in india.


Eligibility criteria:
inclusion criteria: * no fever on day of vaccination * females have a negative pregnancy test and use an acceptable method of birth control, or are postmenopausal * underlying chronic illnesses must be stable exclusion criteria: * history of hypersensitivity reaction to any vaccine component * prior receipt of a varicella or zoster vaccine * prior history of herpes zoster * have recently had another vaccination * have recently received blood products other than autologous blood transfusion * pregnant or breast feeding * use of immunosuppressive therapy * known or suspected immune dysfunction * use of nontopical antiviral therapy with activity against herpesvirus
zimura in combination with eylea in patients with idiopathic polypoidal choroidal vasculopathy (ipcv)

Conditions: Idiopathic Polypoidal Choroidal Vasculopathy

Summary: to asses the safety of intravitreal zimura™ (complement factor c5 inhibitor) administered in combination with eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy


Eligibility criteria:
inclusion criteria: * diagnosis of ipcv * patients must have had 3 sequential eylea injections within the previous 4 months exclusion criteria: * intravitreal treatment in the study eye prior to screening, regardless of indication, except 3 prior injections of eylea * history or evidence of severe cardiac disease * any major surgical procedure within one month of trial entry * subjects with a clinically significant laboratory value * any treatment with an investigational agent in the past 60 days for any condition * women who are pregnant or nursing * known serious allergies to the fluorescein dye, icg dye, iodine, povidone iodine, or to the components or formulation of either zimura or eylea

Keywords: zimura arc1905 eylea aflibercept ipcv avacincaptad pegol complement factor c5 inhibitor
clinical diagnosis and treatment of intracerebral hemorrhage based on artificial intelligence

Conditions: Intracerebral Hemorrhage

Summary: the purpose of this study is to test the reliability and validity of an artificial intelligence system and a related 5-score scale to predict hematoma expansion, and conduct a study cohort of intracerebral hemorrhage to screen out imaging and biological markers that could predict hematoma expansion in real-world.

this is a investigator-initiated, multi-center, prospective, registered cohort study. the study is intended to enroll 4000 patients with intracerebral hemorrhage from 50 hospital in china. clinical and imaging data, as well as the results of laboratory examination will be collected to test the reliability and validity of an artificial intelligence system and a related 5-score scale to predict hematoma expansion, and conduct a study cohort of intracerebral hemorrhage to screen out imaging and biological markers that could predict hematoma expansion in real-world.

Eligibility criteria:
inclusion criteria: 1. diagnosis of spontaneous intracerebral hemorrhage(sich) 2. age ≥18; 3. admission within 24 hours of symptom onset 4. ct available at 24 hours 5. informed consent obtained exclusion criteria: 1. intracerebral hemorrhage caused by tumor, vascular malformation, aneurysm, etc. 2. deep coma at admission (gcs≤8) 3. intended to have a surgery within 24 hours 4. congenital coagulation dysfunction 5. previous intracerebral hematoma have not been absorbed

Keywords: intracerebral hemorrhage hematoma expansion artificial intelligence
small intestinal bacterial overgrowth: a prospective registry

Conditions: Functional Dyspepsia; Small Intestinal Bacterial Overgrowth

Summary: the purpose of this study is to investigate the prevalence of small intestinal bacterial overgrowth (sibo) in patients who will be undergoing an enteroscopy as an outpatient procedure with symptoms of functional dyspepsia. in addition, the investigators would like to identify the types of bacteria that are present in the small intestines in patients with sibo and compare two different diagnostic tools: microbiologic culture and dna sequencing of bacteria. the aim is to compare the microbiota between patients with and without the clinical complications of sibo

same as above

Eligibility criteria:
1.study subjects inclusion criteria i. all patients who are undergoing small bowel aspiration for suspected sibo regardless etiology. exclusion criteria i. use of colon cleansing prep in the past 1 month ii. treatment with antibiotics in the past 30 days (antibiotics are allowable for patients undergoing clinical indicated repeat aspiration to determine bacteria clearance) iii. use of probiotics in the past 30 days iv. contraindication for upper endoscopy for any reason v. prisoners vi. pregnant vii. unable to give own informed consent 2 control subjects inclusion criteria i. patients who are undergoing double balloon enteroscopy or upper enteroscopy for another medical reason. exclusion criteria i. diagnosis of sibo ii. diagnosis of functional dyspepsia iii. established risk factors for sibo (any of the following) 1. connective tissue disorder (scleroderma, polymyositis, mixed connective tissue disease, or systemic lupus 2. resection of ileocecal valve for any reason 3. chronic intestinal pseudo-obstruction 4. small bowel blind limb, diverticulum or fistula 5. surgery with decreased gastric acid exposure for small bowel a. gastric surgery with vagotomy (bilroth i, bilroth ii, vagotomy/pyloroplasty) or gastric bypass iv. use of colon cleansing prep in the past 1 month v. use of antibiotics in the past 30 days vi. use of probiotics in the past 30 days vii. contraindication for upper endoscopy for any reason viii. prisoners ix. pregnant x. unable to give own informed

Keywords: functional dyspepsia post prandial distress syndrome small bowel bacteria overgrowth epigastric pain syndrome diarrhea bloating post prandial fullness weight loss
effect of rigid tapping on chronic functional ankle instability in basketball players

Conditions: Ankle Inversion Sprain

Summary: this study aims rigid tapping on chronic functional ankle instability in professional basketball players.

lateral ankle sprains (lass) are common injuries in sports and physical activities, with up to 40% of individuals experiencing a first-time las developing chronic ankle instability (cai). lass predominantly affect the anterior talofibular ligament, and residual symptoms can persist in a significant percentage of patients. however, many individuals with ankle sprains do not seek professional treatment, leading to potential underestimation of the injury severity. cai is characterized by recurrent episodes of ankle giving way, ongoing symptoms, reduced ankle range of motion, diminished self-reported function, and persistent ankle sprains beyond one year. it is attributed to both mechanical and functional instability, with factors such as proprioceptive deficits and mechanical insufficiencies contributing to the condition. taping, particularly rigid taping, is commonly used by athletes to enhance joint stability and improve dynamic balance and functional performance. rigid taping limits joint movement, improves joint position, and provides external support without compromising functional performance. taping is especially prevalent in multidirectional sports like basketball, where ankle sprains are frequent. the use of tapes aims to restrict ankle movement, increase joint stability, and enhance proprioception without hindering athletic performance.

Eligibility criteria:
inclusion criteria: * basketball players with age range from 18-40 years old. * body mass index (bmi) range from 18-25 h/m2. * participants had episodes of subjective sensation of instability in the last six months. * participants have at least moderate ankle instability, defined as a score of \<25 on the cumberland ankle instability tool (cait). exclusion criteria: * participants had a history of surgery or fractures in the ankle joints. * participants had a neurological or vestibular disorder. * participants were unable to understand the nature of the protocol and test instructions.
artificial intelligence-assisted diagnosis and prognostication in low ejection fraction using electrocardiograms

Conditions: Left Ventricular Systolic Dysfunction (Disorder)

Summary: this is a randomized controlled trial (rct) to test a novel artificial intelligence (ai)-enabled electrocardiogram (ecg)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.


Eligibility criteria:
inclusion criteria: * patients with ef\>50% or without transesophageal echocardiography (tee) exclusion criteria: * patients with a history of heart failure or an ef\<= 35%.
cerebrospinal fluid hemoglobin to monitor for aneurysmal subarachnoid hemorrhage related secondary brain injury

Conditions: Subarachnoid Hemorrhage, Aneurysmal; Vasospasm; Delayed Cerebral Ischemia; Delayed Ischemic Neurological Deficit

Summary: the primary objective of this study is to evaluate the association between hemoglobin levels in the cerebrospinal fluid (csf-hb) and the occurrence of secondary brain injury in patients after aneurysmal subarachnoid hemorrhage (sah-sbi) during the first 14 days after bleeding.

this is an international multicentre observational study to validate cerebrospinal fluid hemoglobin (csf-hb) as a monitoring biomarker for aneurysmal subarachnoid hemorrhage related secondary brain injury (sah-sbi). it is hypothesized that there is an association between the concentration of csf-hb and the occurrence of sah-sbi during the first 14 days after the bleeding (post-sah). the primary objective of this study is to evaluate the association between ventricular csf-hb and sah-sbi during the first 14 days post-sah. the secondary objectives are to investigate: * the association between ventricular csf-hb and angiographic vasospasms (avsp), delayed cerebral ischemia (dci) and delayed ischemic neurological deficits (dind) during the first 14 days post-sah, * the accuracy of ventricular csf-hb to monitor for avsp, dci and dind during the first 14 days post-sah, * the association between lumbar csf-hb and sah-sbi, avsp, dci and dind during the first 14 days post-sah, * the accuracy of lumbar csf-hb to monitor for avsp, dci and dind during the first 14 days post-sah, * the association between baseline measures and csf-hb (ventricular and lumbar during the first 14 days post-sah), * the association between csf-hb (ventricular and lumbar during the first 14 days post-sah) and co-interventions/complications, * the association between csf-hb (ventricular and lumbar during the first 14 days post-sah) and chronic hydrocephalus at 12 weeks follow-up, * the association between csf-hb (ventricular and lumbar during the first 14 days post-sah) and functional outcome at 12 weeks follow-up, * exploratory csf proteome/metabolome analyses to assess hb toxicity, inflammation, neuronal, or vascular damage.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * hospital admission due to an aneurysmal subarachnoid hemorrhage (diagnosis radiologically confirmed) exclusion criteria: * non-aneurysmal subarachnoid hemorrhage (eg. trauma, perimesencephalic subarachnoid hemorrhage). * participation in another study with csf sampling or an interventional medical product within the 30 days preceding and during the present study. * previous enrolment into the current study

Keywords: cerebrospinal fluid hemoglobins